8-K: T2 Biosystems Reports Record Sepsis Test Revenue and Progress on Pipeline in Second Quarter 2024

T2 Biosystems achieved record sepsis test revenue in the second quarter of 2024, driven by increased sales of its T2Bacteria and T2Resistance panels, while also advancing its product pipeline and strengthening its financial position.

Summary

• T2 Biosystems reported second quarter 2024 total revenue of $2.0 million, which was flat compared to the same period last year.
• The company achieved record quarterly and first half sepsis test revenue, growing 27% and 25% respectively year-over-year, primarily due to sales of the T2Bacteria and T2Resistance panels.
• Loss from operations improved by 27% to $9.6 million in Q2 2024, compared to $13.1 million in Q2 2023.
• Net loss for the quarter was $9.2 million, or $0.66 per share, compared to a net loss of $6.3 million, or $7.84 per share, in the prior year period.
• Cash and cash equivalents decreased to $4.2 million as of June 30, 2024, from $6.2 million as of March 31, 2024.
• T2 Biosystems executed contracts for 2 T2Dx Instruments in Q2, both outside the U.S., and an additional 6 contracts in July 2024.
• The company signed multiple international distribution agreements in the Middle East and Asia.
• They converted $30.0 million of term loan debt into equity, reducing debt and quarterly interest payments by approximately 80% from May 2023 levels.
• Clinical studies for the T2Lyme Panel were completed, with a planned launch as a laboratory developed test (LDT) in Q3 2024.
• A 510(k) premarket notification was submitted to the FDA to expand the T2Candida Panel to include pediatric testing.
• The T2Resistance Panel is advancing towards a U.S. FDA 510(k) submission, now expected in Q4 2024.
• New data presented at the ASM Microbe 2024 conference highlighted the clinical benefits of the T2Candida Panel.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong growth in sepsis test revenue and significant debt reduction. However, the net loss and cash burn are concerning, and the delay in the T2Resistance Panel submission tempers the overall positive sentiment.

Positives

• Sepsis test revenue showed strong growth, indicating increasing market adoption of the company's products.
• The reduction in operating losses demonstrates improved cost management and operational efficiency.
• Debt reduction through conversion to equity significantly strengthens the company's balance sheet.
• Expansion into new international markets through distribution agreements provides growth opportunities.
• The launch of the T2Lyme Panel as an LDT offers a new revenue stream and addresses an unmet medical need.
• The company is in negotiations with a multibillion-dollar healthcare company for a potential U.S. commercial partnership.
• The company is consolidating facilities to reduce costs by approximately $1.0 million annually.
• The company is partnering with ADP TotalSource to reduce HR costs by approximately $0.4 million annually.

Negatives

• Total revenue was flat compared to the prior year period, despite growth in sepsis test revenue.
• The company experienced a net loss of $9.2 million for the quarter.
• Cash and cash equivalents decreased from $6.2 million to $4.2 million during the quarter.
• The submission of the T2Resistance Panel to the FDA was delayed to the fourth quarter of 2024.

Risks

• The company's financial results are subject to revision as they have not been audited.
• The company faces risks related to realizing anticipated benefits from contracts, products, and strategic priorities.
• There is a risk of failure to obtain FDA filings or clearances within expected time frames.
• The company's ability to continue as a going concern depends on raising additional debt or equity financing.
• The company is subject to risks related to the blood culture media bottle shortage and its potential impact on the market.
• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company anticipates continued growth in sepsis product revenue, driven by the expanded T2Bacteria Panel, potential U.S. distribution partnerships, and international expansion. They also expect the launch of the T2Lyme Panel and the potential for the T2Biothreat Panel to contribute to future revenue. The company is focused on improving cash flow through cost reduction measures.

Management Comments

• John Sperzel, Chairman and CEO, stated that they are highly encouraged by the record second quarter and first half of 2024 sepsis test revenue.
• John Sperzel noted that the blood culture media bottle shortage represents an opportunity for T2 Biosystems to increase adoption of their direct-from-blood diagnostics.
• Management believes the launch of the T2Lyme Panel as a Laboratory Developed Test (LDT) represents a significant growth opportunity.
• Management is prioritizing enhancing operations and implementing cost reduction measures to improve cash flow.

Industry Context

The announcement comes at a time when there is a critical shortage of blood culture media bottles, which could favor T2 Biosystems' blood culture-independent diagnostic solutions. The company is positioning itself to capitalize on this situation by lobbying for changes to guidelines to include diagnostic products that can detect sepsis-causing pathogens directly from blood. The company is also expanding its international presence and exploring strategic partnerships to accelerate growth.

Comparison to Industry Standards

• T2 Biosystems' direct-from-blood sepsis diagnostics differentiate it from competitors that rely on blood culture, such as Becton Dickinson (BD), whose blood culture media is currently facing supply shortages.
• The company's T2Candida Panel offers faster results compared to traditional methods like beta-D-glucan tests, as demonstrated by the Henry Ford Hospital study, which showed results available 38 hours faster.
• The T2Resistance Panel's high accuracy (94.7% sensitivity and specificity) and rapid turnaround time (4.4 hours) compare favorably to standard microbiology methods, which can take 58.3 hours.
• The company's focus on early detection of Lyme disease with the T2Lyme Panel addresses a gap in current diagnostic methods that rely on antibody tests, which can take 30-60 days post-infection to be accurate.
• The company's expansion into international markets through distribution agreements is a common strategy for medical device companies seeking growth, similar to other companies in the diagnostics space.

Stakeholder Impact

• Shareholders will benefit from the debt reduction and potential for increased revenue growth.
• Employees may experience changes due to headcount reductions and the transition to a PEO.
• Customers will benefit from the availability of new diagnostic tests and faster results.
• Suppliers may be impacted by changes in inventory planning and material management.
• Creditors have seen a significant reduction in debt through the conversion to equity.

Next Steps

• Launch the T2Lyme Panel as a laboratory developed test (LDT) in the third quarter of 2024.
• Submit a 510(k) premarket notification to the FDA for the T2Resistance Panel in the fourth quarter of 2024.
• Continue to pursue a potential U.S. commercial partnership with a multibillion-dollar healthcare company.
• Further consolidate real estate space by exiting the facility at 4 Hartwell Ave and consolidating operations into the headquarters at 101 Hartwell Ave.
• Continue to expand international distribution agreements.
• Submit a 510(k) premarket notification to the FDA to expand the use of the T2Bacteria Panel to include pediatric testing during 2024.

Key Dates

Keywords

sepsis, T2Bacteria, T2Candida, T2Resistance, T2Lyme, diagnostics, FDA, blood culture, antimicrobial resistance, LDT, distribution agreements, debt reduction, financial results